Zynerba Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Stock-based compensation
Loss on disposal of equipment
Changes in operating assets and liabilities:
Incentive and tax receivables
Prepaid expenses and other assets
Deferred grant revenue
Right-of-use assets and liabilities
Accounts payable
Accrued expenses

Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from the issuance of common stock
Payment of financing fees and expenses
Proceeds from the exercise of stock options
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosures of cash flow information:
Financing costs included in accounts payable and accrued expenses at end of year
Property and equipment acquired unpaid at end of period
Property and equipment acquired but unpaid at end of year
Reclassification of deferred rent liability to right-of-use assets upon adoption of ASC 842
Right-of-use assets and lease liability recorded upon adoption of ASC 842

Comments